Published in J Gastroenterol Hepatol on August 01, 2000
Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol (2006) 1.63
Current and future anti-fibrotic therapies for chronic liver disease. Clin Liver Dis (2008) 1.39
Accuracy of hyaluronic acid level for predicting liver fibrosis stages in patients with hepatitis C virus. Comp Hepatol (2005) 1.25
Molecular serum markers of liver fibrosis. Biomark Insights (2012) 1.20
Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease. World J Gastroenterol (2005) 1.19
Grading and staging of hepatic fibrosis, and its relationship with noninvasive diagnostic parameters. World J Gastroenterol (2003) 1.19
Non-invasive assessment of liver fibrosis in chronic hepatitis C. Hepatol Int (2011) 1.15
Non-invasive assessment of liver fibrosis. Ann Gastroenterol (2012) 1.07
Non-invasive assessment of liver fibrosis in chronic liver diseases: implementation in clinical practice and decisional algorithms. World J Gastroenterol (2009) 1.02
Assessing liver fibrosis with serum marker models. Clin Biochem Rev (2007) 1.02
Non-invasive diagnosis of advanced fibrosis and cirrhosis. World J Gastroenterol (2014) 1.00
Correlation of serum liver fibrosis markers with severity of liver dysfunction in liver cirrhosis: a retrospective cross-sectional study. Int J Clin Exp Med (2015) 0.96
Markers of inflammation and fibrosis in alcoholic hepatitis and viral hepatitis C. Int J Hepatol (2012) 0.93
Novel algorithm for non-invasive assessment of fibrosis in NAFLD. PLoS One (2013) 0.93
Chronic hepatitis C and liver fibrosis. World J Gastroenterol (2014) 0.92
Accuracy of a predictive model for severe hepatic fibrosis or cirrhosis in chronic hepatitis C. World J Gastroenterol (2005) 0.91
Staging of liver fibrosis in chronic hepatitis B patients with a composite predictive model: a comparative study. World J Gastroenterol (2010) 0.91
Noninvasive diagnosis of hepatic fibrosis in chronic hepatitis C. World J Gastroenterol (2007) 0.90
Hyaluronic Acid: from biochemical characteristics to its clinical translation in assessment of liver fibrosis. Hepat Mon (2013) 0.87
Factors correlating with acoustic radiation force impulse elastography in chronic hepatitis C. World J Gastroenterol (2014) 0.87
A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation. Virol J (2011) 0.85
Non-invasive diagnosis of liver fibrosis and cirrhosis. World J Gastroenterol (2015) 0.84
A prospective pilot study of circulating endothelial cells as a potential new biomarker in portal hypertension. Liver Int (2009) 0.84
Checkmate to liver biopsy in chronic hepatitis C? World J Gastroenterol (2012) 0.84
Biopsy-controlled liver fibrosis staging using the enhanced liver fibrosis (ELF) score compared to transient elastography. PLoS One (2012) 0.82
Reduced chondrogenic matrix accumulation by 4-methylumbelliferone reveals the potential for selective targeting of UDP-glucose dehydrogenase. Matrix Biol (2011) 0.82
Evaluation of Biomarkers of NAFLD in a Cohort of Morbidly Obese Patients. J Nutr Metab (2011) 0.81
CD44 participates in IP-10 induction in cells in which hepatitis C virus RNA is replicating, through an interaction with Toll-like receptor 2 and hyaluronan. J Virol (2012) 0.81
Progression of Liver Fibrosis in HIV/HCV Co-Infection: A Comparison between Non-Invasive Assessment Methods and Liver Biopsy. PLoS One (2015) 0.78
Liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfection: Diagnostic methods and clinical impact. World J Hepatol (2015) 0.78
Hyaluronic acid concentration in liver diseases. Clin Exp Med (2015) 0.77
Noninvasive evaluation of hepatic fibrosis in children with infant hepatitis syndrome. World J Gastroenterol (2006) 0.76
Biochemical markers of hepatic fibrogenesis: single measurements are not reliable enough to replace liver biopsy. J Gastroenterol Hepatol (2000) 0.76
Non-invasive Markers of Liver Fibrosis: Adjuncts or Alternatives to Liver Biopsy? Front Pharmacol (2016) 0.76
A secreted form of the asialoglycoprotein receptor, sH2a, as a novel potential noninvasive marker for liver fibrosis. PLoS One (2011) 0.76
The treatment of hepatic encephalopathy in the cirrhotic patient. Gastroenterol Hepatol (N Y) (2010) 0.76
Effect of vitamin D therapy on interleukin-6, visfatin, and hyaluronic acid levels in chronic hepatitis C Egyptian patients. Ther Clin Risk Manag (2015) 0.76
Clinical Utility of Biomarkers of Liver Fibrosis. Gastroenterol Hepatol (N Y) (2006) 0.75
Iron overload correlates with serum liver fibrotic markers and liver dysfunction: Potential new methods to predict iron overload-related liver fibrosis in thalassemia patients. United European Gastroenterol J (2016) 0.75
Hyaluronic acid as a biomarker of fibrosis in chronic liver diseases of different etiologies. Clujul Med (2016) 0.75
Serum Liver Fibrosis Markers in the Prognosis of Liver Cirrhosis: A Prospective Observational Study. Med Sci Monit (2016) 0.75
Evaluation of liver fibrosis: "Something old, something new…". Ann Gastroenterol (2016) 0.75
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med (1998) 14.40
Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med (1999) 5.32
A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med (1995) 4.84
Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med (1989) 4.69
A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med (1990) 4.53
Fibrolamellar carcinoma of the liver: a tumor of adolescents and young adults with distinctive clinico-pathologic features. Cancer (1980) 3.82
Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet (1997) 3.11
A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology (2001) 3.02
Cloning and characterization of a Pseudomonas mendocina KR1 gene cluster encoding toluene-4-monooxygenase. J Bacteriol (1991) 3.01
Etiology and outcome for 295 patients with acute liver failure in the United States. Liver Transpl Surg (1999) 2.79
Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med (1984) 2.76
Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy. Hepatology (1999) 2.64
Perinatal hepatitis B virus transmission in the United States. Prevention by passive-active immunization. JAMA (1985) 2.48
Hepatitis B virus, aflatoxins, and hepatocellular carcinoma in southern Guangxi, China. Cancer Res (1989) 2.35
Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin. Final report of the Veterans Administration Cooperative Study. Ann Intern Med (1978) 2.29
Prevalence of hepatitis B and C viral markers in black and white patients with hepatocellular carcinoma in the United States. J Natl Cancer Inst (1990) 2.23
Pathological diagnosis of chronic hepatitis C: a multicenter comparative study with chronic hepatitis B. The Hepatitis Interventional Therapy Group. Gastroenterology (1993) 2.20
Indeterminate hepatitis C. Lancet (1993) 2.17
Sequence and analysis of chromosome 3 of the plant Arabidopsis thaliana. Nature (2000) 2.17
Failure of Centers for Disease Control criteria to identify hepatitis B infection in a large municipal obstetrical population. Ann Intern Med (1987) 2.14
Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study. Hepatology (2001) 2.13
Yeast-recombinant hepatitis B vaccine. Efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission. JAMA (1987) 2.08
Hepatitis C-associated hepatocellular carcinoma. Hepatology (1990) 2.07
Surveillance for hepatocellular carcinoma in patients with chronic viral hepatitis in the United States of America. J Gastroenterol Hepatol (2001) 2.06
Coagulation defects associated with massive blood transfusions. Ann Surg (1971) 2.03
Characterization of the kinetics of the passive and active transport mechanisms for bile acid absorption in the small intestine and colon of the rat. J Clin Invest (1972) 2.00
The role of laparoscopy in the diagnosis of cirrhosis. Gastrointest Endosc (1996) 1.89
Hepatitis-associated antigen and hepatocellular carcinoma in Taiwan. Ann Intern Med (1971) 1.89
Intrahepatic, nucleocapsid antigen-specific T cells in chronic active hepatitis B. J Immunol (1987) 1.85
Large cystic lesions of the liver in adults: a 15-year experience in a tertiary center. J Am Coll Surg (2001) 1.79
Benign and solid tumors of the liver: relationship to sex, age, size of tumors, and outcome. Am Surg (2001) 1.72
Splenic epidermoid cysts. Ann Surg (1978) 1.68
Evaluation of monovalent influenza vaccine in a retirement community during the epidemic of 1965-66. JAMA (1969) 1.67
Impact of virologic breakthrough and HBIG regimen on hepatitis B recurrence after liver transplantation. Am J Transplant (2010) 1.67
Role of viral load in heterosexual transmission of human immunodeficiency virus type 1 by blood transfusion recipients. Transfusion Safety Study Group. Am J Epidemiol (1997) 1.62
A serologic follow-up of the 1942 epidemic of post-vaccination hepatitis in the United States Army. N Engl J Med (1987) 1.61
Lymphocyte stimulation in hepatitis B infections. N Engl J Med (1975) 1.60
Efficacy of hepatitis B immune serum globulin after accidental exposure. Preliminary report of the Veterans Administration Cooperative Study. Lancet (1975) 1.59
Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology (1999) 1.59
Septic complications of war wounds. JAMA (1972) 1.58
Lack of response to recombinant hepatitis B vaccine in nonresponders to the plasma vaccine. JAMA (1988) 1.56
Cell-mediated hepatic injury in alcoholic liver disease. Veterans Affairs Cooperative Study Group 275. Gastroenterology (1993) 1.52
Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. Gastroenterology (1995) 1.51
Nonviral risk factors for hepatocellular carcinoma in a low-risk population, the non-Asians of Los Angeles County, California. J Natl Cancer Inst (1991) 1.50
The comparative survivals of alcoholics versus nonalcoholics after distal splenorenal shunt. Ann Surg (1978) 1.49
Hepatitis C infection by polymerase chain reaction in alcoholics: false-positive ELISA results and the influence of infection on a clinical prognostic score. Am J Gastroenterol (1993) 1.48
A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation. Liver Transpl (2001) 1.47
Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States. J Viral Hepat (2000) 1.45
Microsporidan hepatitis in the acquired immunodeficiency syndrome. Ann Intern Med (1987) 1.45
Perinatal transmitted acute icteric hepatitis B in infants born to hepatitis B surface antigen-positive and anti-hepatitis Be-positive carrier mothers. Pediatrics (1982) 1.44
Laparoscopic evaluation of liver disease in chronic renal failure prior to renal transplantation. Gastrointest Endosc (1997) 1.42
Autoimmune cholangitis with features of autoimmune hepatitis: successful treatment with immunosuppressive agents and ursodeoxycholic acid. J Gastroenterol Hepatol (2000) 1.40
The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology (1999) 1.39
Hepatitis delta virus. No longer a defective virus. Am J Clin Pathol (1992) 1.39
Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. J Hepatol (2001) 1.38
Primary hepatocellular carcinoma following perinatal transmission of hepatitis B. West J Med (1988) 1.38
Resolution of a contraceptive-steroid-induced hepatic adenoma with subsequent evolution into hepatocellular carcinoma. Ann Intern Med (1986) 1.31
Twenty years of the German Environmental Survey (GerES): human biomonitoring--temporal and spatial (West Germany/East Germany) differences in population exposure. Int J Hyg Environ Health (2007) 1.30
Clinical and bacteriological evaluation of antibiotic treatment in shigellosis. JAMA (1970) 1.29
Hepatitis in dental professionals. JAMA (1975) 1.27
Fulminant or subfulminant non-A, non-B viral hepatitis: the role of hepatitis C and E viruses. Gastroenterology (1993) 1.27
Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group. Hepatology (1997) 1.25
Viral pathogenesis of hepatocellular carcinoma in the United States. Hepatology (1993) 1.23
German health-related environmental monitoring: assessing time trends of the general population's exposure to heavy metals. Int J Hyg Environ Health (2013) 1.23
Prevalence of antibodies to hepatitis C virus among patients with cryptogenic chronic hepatitis and cirrhosis. Hepatology (1992) 1.22
Prospective multicenter clinical evaluation of AMPLICOR and COBAS AMPLICOR hepatitis C virus tests. J Clin Microbiol (2001) 1.22
Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study. Gastroenterology (1997) 1.21
Impact of histological grade of hepatocellular carcinoma on the outcome of liver transplantation. Arch Surg (2001) 1.21
Cirrhosis associated with partial deficiency of alpha-1 antitrypsin in an adult. Ann Intern Med (1973) 1.21
Evaluation of hepatitis B and C viral markers: clinical significance in Asian and Caucasian patients with hepatocellular carcinoma in the United States of America. J Gastroenterol Hepatol (1996) 1.21
Assessing health-related quality of life in chronic hepatitis C using the Sickness Impact Profile. Clin Ther (1994) 1.20
Hepatic dysfunction in recipients of renal allografts. Surg Gynecol Obstet (1975) 1.19
New perspectives in the diagnosis of hepatitis C. Semin Liver Dis (1999) 1.18
Prevalence of hepatitis C and G virus infection in chronic hemodialysis patients. Am J Kidney Dis (1998) 1.17
Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology (1997) 1.17
Transfusion transmission of retroviruses: human T-lymphotropic virus types I and II compared with human immunodeficiency virus type 1. Transfusion (1994) 1.16
Amoxicillin-clavulanate potassium-associated cholestasis. Gastroenterology (1989) 1.16
Patients co-infected with human immunodeficiency virus and hepatitis C virus demonstrate higher levels of hepatic HCV RNA. J Viral Hepat (1999) 1.16
A comparative study of hepatitis B viral markers in the family members of Asian and non-Asian patients with hepatitis B surface antigen-positive hepatocellular carcinoma and with chronic hepatitis B infection. J Infect Dis (1979) 1.15
Prevention of maternal-infant hepatitis B virus transmission by immunization: the role of serum hepatitis B virus DNA. Hepatology (1986) 1.13
Survival after distal splenorenal shunt. Surg Gynecol Obstet (1977) 1.12
The effect of the distal splenorenal shunt on hypersplenism. Ann Surg (1977) 1.12
An institutional outbreak of hepatitis B related to a human biting carrier. J Infect Dis (1982) 1.11
Randomized, cross-over, controlled comparison of two inactivated hepatitis A vaccines. Vaccine (2000) 1.11
A study of oral nutritional support with oxandrolone in malnourished patients with alcoholic hepatitis: results of a Department of Veterans Affairs cooperative study. Hepatology (1993) 1.10
Spontaneous group B Salmonella enteritidis peritonitis in cirrhotic ascites and acquired immune deficiency syndrome. Am J Gastroenterol (1988) 1.10
Regulation of hepatic glycogen synthetase. Stimulation of glycogen synthetase in an in vitro liver system by insulin bound to sepharose. J Biol Chem (1971) 1.09
Prolonged intrahepatic cholestasis secondary to acute hepatitis A. Ann Intern Med (1984) 1.08
Alterations in the immune response of nonresponders to the hepatitis B vaccine. J Infect Dis (1985) 1.07
Clinical trial: the efficacy and safety of oral PF-03491390, a pancaspase inhibitor - a randomized placebo-controlled study in patients with chronic hepatitis C. Aliment Pharmacol Ther (2010) 1.07
Protein energy malnutrition in severe alcoholic hepatitis: diagnosis and response to treatment. The VA Cooperative Study Group #275. JPEN J Parenter Enteral Nutr (1996) 1.06
Hepatic epithelioid hemangioendothelioma. Radiology (1988) 1.06
Re-treatment of chronic hepatitis C with consensus interferon . Hepatology (1998) 1.05